Inclunox
Enoxaparin sodium biosimilar developed by Sandoz. Reference product Clexane (Lovenox in the United States).
About Inclunox
Inclunox is Sandoz's enoxaparin for Canada, approved in November 2020, with a higher-strength form. Sandoz sells enoxaparin as a generic in the United States and as a biosimilar in Canada, reflecting the two countries' different rules.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan
Not listed by PMDA.
Canada · Inclunox
Health CanadaApprovedIndia
Not listed by CDSCO.
United Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Inclunox holds an approval, these are the other enoxaparin sodium biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| HC | 4 | Baxter (Axberi), Fresenius Kabi (Elonox), Juno Pharma Canada (Noromby), Techdow (Inhixa) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Sandoz: Binocrit / Epoetin alfa Hexal / Abseamed, Enzeevu / Afqlir, Erelzi, Hyrimoz / Hefiya, Jubbonti / Wyost, Omnitrope, Rixathon / Riximyo, Zarxio / Zarzio, Ziextenzo.
Chronology
- HCNov 2020Notice of Compliance, Health Canada
Sources
Planning enoxaparin sodium biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant